Medisieve

Haemofilter removing magnetic agents from bloodstream.

Dialysis nurse checking machine, writing on clipboard

Medisieve Ltd is a company that is commercialising a haemofilter capable of removing magnetic or magnetically-labelled agents (Magnetic Beads) directly from a patient’s bloodstream in a dialysis-like technique.

It has an initial focus on malaria-infected red blood cells, but the Magnetic Beads system can be designed to bind specifically to various different agents in blood, enabling the Magnetic Blood Filtration Platform to be adapted to different indications.

The spinout is exploring opportunities in acute hyperinflammation, gene therapies, oncology and severe malaria.

The Medisieve journey so far:

2014: spinout founded at UCL
2020: UKRI grant of £1.6 million to support first in human trials of IL-6-driven hyperinflammation programme
2021: £1.8 million additional funding to advance in-human trials, led by 24Haymarket.
2022: Phase 1 clinical trial for IL-6 met all primary and secondary endpoints, demonstrating safety and efficacy.

Team

Professor Quentin Pankhurst

Founder

Professor of Physics and Director of Healthcare Biomagnetics Laboratory at UCL. In 2011, he set up the Institute of Biomedical Engineering based on translational research and experimental medicine.

Dr. George Frodsham

Co-founder and CEO

Dr Frodsham holds a PhD in Biochemical Engineering and serves as MediSieve's CEO. Recently George was awarded BBSRC Innovator of the Year and was named one of MIT 35 Innovators Under 35.

Dr Weng Sie Wong

Senior Business Manager

UCL Hawkes Institute

Dr Wong brings extensive experience of all aspects of university technology transfer activities from strategic IP management to licence negotiations and spinout formation.